Early aggressive treatment in patients whose cancer is likely to progress slowly, if at all, causes side-effects and reduces their quality of life for no benefit. Can active surveillance avoid this?
Related Articles
Spotlight on
Newsround
Featured
Silke Gillessen: tackling uncertainties and access in advanced prostate cancer
Impact Factor